PDL BioPharma, Inc.
PDLIV
NASDAQ
Recommendation
Prev Close
--
Volume
--
Avg Vol (90D)
--
Market Cap
--
Dividend & Yield
--
52-Week Range
-- - --
P/E (TTM)
--
EPS (TTM)
| 08/31/2020 | 06/30/2020 | 03/31/2020 | 12/31/2019 | 09/30/2019 | |
|---|---|---|---|---|---|
| Net Income | -81.69M | -- | -- | -- | -- |
| Total Depreciation and Amortization | 1.87M | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 485.00K | -- | -- | -- | -- |
| Total Other Non-Cash Items | 70.07M | -- | -- | -- | -- |
| Change in Net Operating Assets | -22.82M | -- | -- | -- | -- |
| Cash from Operations | -51.23M | -- | -- | -- | -- |
| Capital Expenditure | -235.00K | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 24.97M | -- | -- | -- | -- |
| Cash from Investing | 45.45M | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -18.85M | -- | -- | -- | -- |
| Issuance of Common Stock | 461.00K | -- | -- | -- | -- |
| Repurchase of Common Stock | -39.37M | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -9.00K | -- | -- | -- | -- |
| Other Financing Activities | -3.02M | -- | -- | -- | -- |
| Cash from Financing | -163.18M | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -168.95M | -- | -- | -- | -- |